{"id":172,"date":"2026-08-25T21:54:54","date_gmt":"2026-08-25T19:54:54","guid":{"rendered":"https:\/\/www.veyronalabs.com\/?post_type=product&#038;p=172"},"modified":"2026-10-15T19:05:51","modified_gmt":"2026-10-15T17:05:51","slug":"retatrutid-10-mg","status":"publish","type":"product","link":"https:\/\/www.veyronalabs.com\/sk\/product\/retatrutide-10-mg\/","title":{"rendered":"Retatrutid (RETA) \u2013 10 mg \/ 20 mg \/ 30 mg"},"content":{"rendered":"<style>\n<p>.vl-reta{--gold:#c99a2e;--ink:#171b24;--muted:#667085;--line:#e6e8ec;--soft:#f7f5f0;max-width:1180px;margin:0 auto;color:var(--ink);font-size:16px;line-height:1.7}<\/p>\n<p>.vl-reta *{box-sizing:border-box}.vl-reta h2,.vl-reta h3,.vl-reta h4{color:var(--ink);line-height:1.18;margin-top:0}.vl-reta h2{font-size:clamp(28px,4vw,44px);letter-spacing:-.02em}.vl-reta h3{font-size:clamp(22px,3vw,30px)}.vl-reta h4{font-size:17px;margin-bottom:7px}.vl-reta p{margin:0 0 16px}.vl-reta a{color:#9a6e0b;text-decoration:underline;text-underline-offset:3px}.vl-kicker{color:var(--gold);font-size:12px;font-weight:800;letter-spacing:.18em;text-transform:uppercase;margin-bottom:10px}.vl-lead{font-size:20px;line-height:1.55;color:#3f4652;max-width:880px}.vl-section{padding:54px 0;border-top:1px solid var(--line)}.vl-section:first-of-type{border-top:0}.vl-grid{display:grid;grid-template-columns:repeat(4,1fr);gap:16px;margin-top:28px}.vl-grid.three{grid-template-columns:repeat(3,1fr)}.vl-grid.two{grid-template-columns:repeat(2,1fr)}.vl-card{background:#fff;border:1px solid var(--line);border-radius:14px;padding:24px;box-shadow:0 8px 28px rgba(16,24,40,.055)}.vl-card.gold{border-top:3px solid var(--gold)}.vl-card p,.vl-card span{color:var(--muted)}.vl-number{display:block;color:var(--gold)!important;font-size:34px;font-weight:800;line-height:1.1;margin-bottom:8px}.vl-label{display:block;font-size:12px;font-weight:800;letter-spacing:.1em;text-transform:uppercase;color:#7a5b16!important;margin-bottom:8px}.vl-dark{background:#101216;color:#fff;border-radius:18px;padding:38px;margin:20px 0}.vl-dark h2,.vl-dark h3,.vl-dark h4{color:#fff}.vl-dark p{color:#d5d8df}.vl-receptor{border-top:3px solid var(--gold)}.vl-receptor .vl-symbol{display:inline-flex;width:48px;height:48px;align-items:center;justify-content:center;border-radius:50%;background:#17191e;color:#e0b651;font-weight:800;margin-bottom:16px}.vl-callout{border-left:4px solid var(--gold);background:var(--soft);padding:22px 24px;border-radius:0 12px 12px 0}.vl-table{width:100%;border-collapse:separate;border-spacing:0;border:1px solid var(--line);border-radius:14px;overflow:hidden}.vl-table th,.vl-table td{padding:15px 18px;border-bottom:1px solid var(--line);text-align:left;vertical-align:top}.vl-table th{width:32%;background:#f8f8f8;color:#333}.vl-table tr:last-child th,.vl-table tr:last-child td{border-bottom:0}.vl-coa{display:grid;grid-template-columns:1.25fr .75fr;gap:28px;align-items:center;background:#111318;color:#fff;border-radius:18px;padding:38px}.vl-coa h2,.vl-coa h3{color:#fff}.vl-coa p{color:#cdd0d6}.vl-metrics{display:grid;grid-template-columns:1fr 1fr;gap:12px}.vl-metric{background:#1c1f25;border:1px solid #343842;border-radius:12px;padding:18px}.vl-metric strong{display:block;color:#e0b651;font-size:25px}.vl-btn{display:inline-block;background:var(--gold);color:#111!important;text-decoration:none!important;font-weight:800;padding:12px 20px;border-radius:6px;margin-top:8px}.vl-refs{padding-left:20px}.vl-refs li{margin-bottom:13px}.vl-status{background:#f8f6f1;border:1px solid #ded7c7;border-radius:14px;padding:26px}.vl-note{font-size:14px;color:var(--muted)}<\/p>\n<p>@media(max-width:900px){.vl-grid,.vl-grid.three{grid-template-columns:1fr 1fr}.vl-coa{grid-template-columns:1fr}.vl-section{padding:40px 0}}<\/p>\n<p>@media(max-width:600px){.vl-grid,.vl-grid.three,.vl-grid.two{grid-template-columns:1fr}.vl-card{padding:20px}.vl-dark,.vl-coa{padding:25px 20px}.vl-table th,.vl-table td{display:block;width:100%}.vl-table th{border-bottom:0;padding-bottom:4px}.vl-table td{padding-top:4px}.vl-metrics{grid-template-columns:1fr 1fr}}<\/p>\n<p>.vl-tech{margin-top:28px;border:1px solid rgba(201,154,46,.42);border-radius:18px;overflow:hidden;background:#111318;color:#fff;box-shadow:0 14px 36px rgba(17,19,24,.13)}\n.vl-tech-head{display:flex;justify-content:space-between;align-items:flex-end;gap:24px;padding:20px 22px;border-bottom:1px solid rgba(201,154,46,.30);background:linear-gradient(135deg,#0d0f13,#171a20)}\n.vl-tech-head span{color:#d7ae4f;font-size:12px;font-weight:800;letter-spacing:.13em;text-transform:uppercase}\n.vl-tech-head strong{color:#d9dce2;font-size:13px;font-weight:600;text-align:right}\n.vl-tech-body{background:#14171c}\n.vl-tech-row{display:grid;grid-template-columns:minmax(155px,.72fr) minmax(0,1.55fr);gap:24px;padding:15px 22px;border-bottom:1px solid rgba(255,255,255,.09)}\n.vl-tech-row:last-child{border-bottom:0}\n.vl-tech-row span{color:#d7ae4f;font-size:13px;font-weight:750}\n.vl-tech-row strong{color:#f5f5f6;font-size:14px;font-weight:600;line-height:1.55;overflow-wrap:anywhere}\n@media(max-width:680px){.vl-tech-head{display:block;padding:18px 16px}.vl-tech-head strong{display:block;margin-top:6px;text-align:left;font-size:12px}.vl-tech-row{grid-template-columns:1fr;gap:4px;padding:13px 16px}.vl-tech-row span{font-size:11px;letter-spacing:.04em;text-transform:uppercase}.vl-tech-row strong{font-size:13px}}\n<\/style>\n<div class=\"vl-reta\">\n<section class=\"vl-section\">\n<div class=\"vl-kicker\">V\u00fdskumn\u00fd profil Veyrona Labs<\/div>\n<h2>Retatrutid (RETA) \u2013 GLP3-R3TA (LY3437943)<\/h2>\n<p class=\"vl-lead\">Sk\u00faman\u00fd jednomolekulov\u00fd agonista navrhnut\u00fd tak, aby p\u00f4sobil na receptory GIP, GLP-1 a glukag\u00f3n \u2013 tri prepojen\u00e9 sign\u00e1lne syst\u00e9my sk\u00faman\u00e9 v oblasti metabolickej regul\u00e1cie, energetickej rovnov\u00e1hy a gluk\u00f3zovej homeost\u00e1zy.<\/p>\n<div class=\"vl-tech\" aria-label=\"Technick\u00e9 \u00fadaje o produkte\">\n<div class=\"vl-tech-head\"><span>Technick\u00e9 \u00fadaje o produkte<\/span><strong>Kvalita a identita na prv\u00fd poh\u013ead<\/strong><\/div>\n<div class=\"vl-tech-body\">\n<div class=\"vl-tech-row\"><span>\u010cistota \/ anal\u00fdza<\/span><strong>10 mg \u0161ar\u017ea RT10-26001: \u010distota 99,71 TP3T (HPLC), nameran\u00fd obsah 10,43 mg; \u010fal\u0161ie varianty s\u00fa \u0161pecifick\u00e9 pre dan\u00fa \u0161ar\u017eu<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Fyzick\u00e1 podoba<\/span><strong>lyofilizovan\u00fd v\u00fdskumn\u00fd materi\u00e1l<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Deklarovan\u00fd obsah<\/span><strong>10 mg \/ 20 mg \/ 30 mg \u2013 volite\u013en\u00fd variant<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Obal<\/span><strong>1 uzavret\u00e1 laborat\u00f3rna f\u013ea\u0161ti\u010dka<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Typ peptidu<\/span><strong>Modifikovan\u00fd trojit\u00fd agonistick\u00fd peptid GIPR \/ GLP-1R \/ GCGR<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Molekul\u00e1rny vzorec<\/span><strong>C221H342N46O68<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Molekulov\u00e1 hmotnos\u0165<\/span><strong>4731,3 g\/mol<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>\u010c\u00edslo CAS<\/span><strong>2381089-83-2<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Skladovanie \u2013 neotvoren\u00fd pr\u00e1\u0161ok<\/span><strong>Uchov\u00e1vajte uzavret\u00fa lyofilizovan\u00fa injek\u010dn\u00fa liekovku pri teplote -20 \u00b0C, such\u00fa a chr\u00e1nen\u00fa pred svetlom. Pred otvoren\u00edm nechajte uzavret\u00fa injek\u010dn\u00fa liekovku dosiahnu\u0165 izbov\u00fa teplotu, aby sa obmedzila kondenz\u00e1cia.<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Skladovanie \u2013 po zmie\u0161an\u00ed s vodou s obsahom kyseliny acetylsalicylovej<\/span><strong>Po pr\u00edprave s bakteriostatickou vodou uchov\u00e1vajte v chladni\u010dke pri teplote 2 \u2013 8 \u00b0C a chr\u00e1\u0148te pred svetlom. Nezmrazujte; minimalizujte opakovan\u00e9 ohrievanie a chladenie.<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Rozpustnos\u0165 \/ rekon\u0161tit\u00facia<\/span><strong>10 mg: <span>Bakteriostatick\u00e1 voda \u2014 1 ml na vialku<\/span><br \/>20 mg: <span>Bakteriostatick\u00e1 voda \u2014 2 ml na vialku<\/span><br \/>30 mg: <span>Bakteriostatick\u00e1 voda \u2014 3 ml na vialku<\/span><\/strong><\/div>\n<\/div>\n<\/div>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-kicker\">Vedeck\u00e9 pozadie<\/div>\n<h2>\u010co je Retatrutid (RETA \/ GLP3-R3TA)?<\/h2>\n<p>GLP3-R3TA, tie\u017e ozna\u010dovan\u00fd ako LY3437943, je syntetick\u00fd peptid vyvinut\u00fd ako trojit\u00fd agonista gluk\u00f3zo-dependentn\u00e9ho inzulinotropn\u00e9ho polypeptidov\u00e9ho receptora (GIPR), receptora glukag\u00f3nu podobn\u00e9ho peptidu-1 (GLP-1R) a glukag\u00f3nov\u00e9ho receptora (GCGR). Na rozdiel od jednotliv\u00fdch agonistov receptora GLP-1 alebo du\u00e1lnych agonistov receptora GIP\/GLP-1, jeho dizajn prid\u00e1va aktivitu glukag\u00f3nov\u00e9ho receptora k profilu inkret\u00ednovej signaliz\u00e1cie.<\/p>\n<p>Molekula pre\u0161la od ranej farmakol\u00f3gie a \u0161t\u00fadi\u00ed f\u00e1zy 1 do \u0161irok\u00e9ho programu klinick\u00e9ho v\u00fdvoja f\u00e1zy 3. Publikovan\u00fd v\u00fdskum teraz zah\u0155\u0148a aktivitu receptorov, odpove\u010f na d\u00e1vku, zmenu telesnej hmotnosti a \u0161irok\u00fa \u0161k\u00e1lu kardiometabolick\u00fdch markerov.<\/p>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-kicker\">Tri dopl\u0148uj\u00face sa cesty<\/div>\n<h2>Mechanizmus \u00fa\u010dinku<\/h2>\n<p class=\"vl-lead\">Retatrutid je navrhnut\u00fd tak, aby aktivoval tri receptory spriahnut\u00e9 s G-prote\u00ednom triedy B. Vedeck\u00fd z\u00e1ujem sa s\u00fastred\u00ed sp\u00f4r na rovnov\u00e1hu t\u00fdchto sign\u00e1lov ne\u017e na ktor\u00fdko\u013evek receptor p\u00f4sobiaci izolovane.<\/p>\n<div class=\"vl-grid three\">\n<div class=\"vl-card vl-receptor\"><span class=\"vl-symbol\">GIP<\/span><\/p>\n<h3>GIP receptor<\/h3>\n<p>Signaliz\u00e1cia GIPR sa podie\u013ea na endokrinnej aktivite reaguj\u00facej na \u017eiviny, vr\u00e1tane gluk\u00f3zou-indukovanej sekr\u00e9cie inzul\u00ednu. V syst\u00e9me s trojit\u00fdm agonistom sa sk\u00fama popri aktivite GLP-1R a GCGR ako s\u00fa\u010das\u0165 integrovanej metabolickej odpovede.<\/p>\n<\/div>\n<div class=\"vl-card vl-receptor\"><span class=\"vl-symbol\">GLP-1<\/span><\/p>\n<h3>GLP-1 receptor<\/h3>\n<p>Aktiv\u00e1cia GLP-1R je spojen\u00e1 so sinaliz\u00e1ciou v pankrease z\u00e1vislou od gluk\u00f3zy, centr\u00e1lnymi dr\u00e1hami chuti do jedla a \u00fa\u010dinkami na vypr\u00e1zd\u0148ovanie \u017eal\u00fadka. Relat\u00edvny pr\u00edspevok ka\u017edej dr\u00e1hy z\u00e1vis\u00ed od expoz\u00edcie, rovnov\u00e1hy receptorov a experiment\u00e1lneho modelu.<\/p>\n<\/div>\n<div class=\"vl-card vl-receptor\"><span class=\"vl-symbol\">GCG<\/span><\/p>\n<h3>Glukag\u00f3nov\u00fd receptor<\/h3>\n<p>Signaling GCGR prid\u00e1va biol\u00f3giu mobiliz\u00e1cie pe\u010de\u0148ov\u00fdch substr\u00e1tov a v\u00fddaja energie. Jeho za\u010dlenenie odli\u0161uje retatrutid od jedno- a dvoj-inkret\u00ednov\u00fdch pr\u00edstupov a je hlavn\u00fdm zameran\u00edm mechanistick\u00e9ho v\u00fdskumu.<\/p>\n<\/div>\n<\/div>\n<div class=\"vl-callout\" style=\"margin-top:24px\"><strong>Integrovan\u00e1 signaliz\u00e1cia:<\/strong> Predklinick\u00fd a klinick\u00fd v\u00fdskum sk\u00fama, ako kombinovan\u00e9 zapojenie receptorov ovplyv\u0148uje nervov\u00fa signaliz\u00e1ciu s\u00favisiacu s chu\u0165ou do jedla, regul\u00e1ciu gluk\u00f3zy, nar\u00e1banie s lipidmi, pe\u010de\u0148ov\u00fd metabolizmus a celkov\u00fa energetick\u00fa rovnov\u00e1hu. Pozorovan\u00e9 klinick\u00e9 v\u00fdsledky nemo\u017eno prip\u00edsa\u0165 len jedn\u00e9mu receptoru.<\/div>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-kicker\">Oblasti v akt\u00edvnom vy\u0161etrovan\u00ed<\/div>\n<h2>K\u013e\u00fa\u010dov\u00e9 oblasti v\u00fdskumu<\/h2>\n<div class=\"vl-grid two\">\n<div class=\"vl-card\">\n<h4>Telesn\u00e1 hmotnos\u0165 a energetick\u00e1 bilancia<\/h4>\n<p>Zmeny telesnej hmotnosti, obvodu p\u00e1sa a ukazovate\u013eov energetickej rovnov\u00e1hy z\u00e1visl\u00e9 od d\u00e1vky boli k\u013e\u00fa\u010dov\u00fdmi sledovan\u00fdmi ukazovate\u013emi v \u0161t\u00fadi\u00e1ch zameran\u00fdch na obezitu.<\/p>\n<\/div>\n<div class=\"vl-card\">\n<h4>Glykemick\u00e1 regul\u00e1cia<\/h4>\n<p>\u0160t\u00fadie zameran\u00e9 na cukrovku 2. typu sk\u00famaj\u00fa HbA1c, glyk\u00e9miu nala\u010dno a interakciu sign\u00e1lnych dr\u00e1h inkret\u00ednu a glukag\u00f3nov\u00e9ho receptora.<\/p>\n<\/div>\n<div class=\"vl-card\">\n<h4>Tuk v pe\u010deni a metabolizmus lipidov<\/h4>\n<p>\u0160pecializovan\u00e9 anal\u00fdzy hodnotili obsah tuku v pe\u010deni, triglyceridy a \u010fal\u0161ie markery metabolick\u00e9ho zdravia pe\u010dene.<\/p>\n<\/div>\n<div class=\"vl-card\">\n<h4>Kardiometabolick\u00e9 rizikov\u00e9 markery<\/h4>\n<p>Klinick\u00e9 programy zah\u0155\u0148aj\u00fa krvn\u00fd tlak, non-HDL cholesterol, markery s\u00favisiace so z\u00e1palom a kardiovaskul\u00e1rne v\u00fdsledky.<\/p>\n<\/div>\n<\/div>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-kicker\">Klinick\u00e9 d\u00f4kazy u \u013eud\u00ed<\/div>\n<h2>\u010co hovor\u00ed v\u00fdskum?<\/h2>\n<p>Ni\u017e\u0161ie uveden\u00e9 \u0161t\u00fadie predstavuj\u00fa v\u00fdsledky z definovan\u00fdch skup\u00edn klinick\u00fdch sk\u00fa\u0161ok spolu s ich trvan\u00edm, d\u00e1vkou a dizajnom \u0161t\u00fadie, v\u010faka \u010domu je v\u00fdvojov\u00fd program na prv\u00fd poh\u013ead \u013eahko porovnate\u013en\u00fd.<\/p>\n<div class=\"vl-grid two\">\n<div class=\"vl-card gold\"><span class=\"vl-label\">Klinick\u00e1 \u0161t\u00fadia obezity f\u00e1zy 2 \u00b7 338 \u00fa\u010dastn\u00edkov<\/span><span class=\"vl-number\">\u221224,21 TP3T<\/span><\/p>\n<h4>Priemern\u00e1 zmena telesnej hmotnosti po 48 t\u00fd\u017ed\u0148och<\/h4>\n<p>Skupina s d\u00e1vkou 12 mg dosiahla priemern\u00fa zmenu \u221217,51 TP3T po 24 t\u00fd\u017ed\u0148och a \u221224,21 TP3T po 48 t\u00fd\u017ed\u0148och. V skupine s placebom bola zmena \u22122,11 TP3T po 48 t\u00fd\u017ed\u0148och. \u0160t\u00fadia bola randomizovan\u00e1, dvojito zaslepen\u00e1 a placebom kontrolovan\u00e1.<\/p>\n<\/div>\n<div class=\"vl-card gold\"><span class=\"vl-label\">TRIUMPH-4 \u00b7 \u00dadaje z hlavnej anal\u00fdzy 3. f\u00e1zy<\/span><span class=\"vl-number\">\u221228,71 TP3T<\/span><\/p>\n<h4>Priemern\u00e1 zmena telesnej hmotnosti po 68 t\u00fd\u017ed\u0148och<\/h4>\n<p>Hl\u00e1sen\u00e9 pre 12 mg skupinu u \u00fa\u010dastn\u00edkov s obezitou alebo nadv\u00e1hou a osteoartr\u00f3zou kolena. Hodnotili sa aj ukazovatele bolesti a fyzick\u00fdch funkci\u00ed pod\u013ea WOMAC. \u00dapln\u00e1 recenzovan\u00e1 publikacija by sa mala odli\u0161ova\u0165 od predbe\u017en\u00fdch v\u00fdsledkov hl\u00e1sen\u00fdch spolo\u010dnos\u0165ou.<\/p>\n<\/div>\n<div class=\"vl-card gold\"><span class=\"vl-label\">TRIUMPH-1 \u00b7 Hlavn\u00e9 v\u00fdsledky \u0161t\u00fadie 3. f\u00e1zy<\/span><span class=\"vl-number\">\u221228,31 TP3T<\/span><\/p>\n<h4>Priemern\u00e1 zmena telesnej hmotnosti v 80. t\u00fd\u017edni<\/h4>\n<p>U \u00fa\u010dastn\u00edkov bez cukrovky dosiahlo 45,31 TP3T z t\u00fdch, ktor\u00ed boli zaraden\u00ed do skupiny s d\u00e1vkou 12 mg, zn\u00ed\u017eenie telesnej hmotnosti aspo\u0148 o 301 TP3T. O vopred stanovenom pred\u013a\u017een\u00ed \u0161t\u00fadie pre pacientov s vy\u0161\u0161\u00edm BMI, ktor\u00e9 trvalo a\u017e 104 t\u00fd\u017ed\u0148ov, sa pod\u00e1vala samostatn\u00e1 spr\u00e1va.<\/p>\n<\/div>\n<div class=\"vl-card gold\"><span class=\"vl-label\">TRIUMPH-2 \u00b7 Predbe\u017en\u00e9 \u00fadaje f\u00e1zy 3<\/span><span class=\"vl-number\">\u221220,81 TP3T<\/span><\/p>\n<h4>Priemern\u00e1 zmena telesnej hmotnosti v 80. t\u00fd\u017edni<\/h4>\n<p>Hl\u00e1sen\u00e9 pre 12 mg skupinu u dospel\u00fdch s diabetom 2. typu a obezitou alebo nadv\u00e1hou spolu s priemern\u00fdm zn\u00ed\u017een\u00edm HbA1c a\u017e o pribli\u017ene 1,6 percentu\u00e1lneho bodu v r\u00e1mci anal\u00fdzy uv\u00e1dzan\u00e9ho programu.<\/p>\n<\/div>\n<\/div>\n<div class=\"vl-callout\" style=\"margin-top:24px\"><strong>D\u00f4kazy v kontexte.<\/strong> Gastrointestin\u00e1lne ne\u017eiaduce \u00fa\u010dinky \u2013 vr\u00e1tane nevo\u013enosti, hna\u010dky, vracania a z\u00e1pchy \u2013 boli naj\u010dastej\u0161ie hl\u00e1sen\u00fdmi \u00fa\u010dinkami v klinick\u00fdch \u0161t\u00fadi\u00e1ch a vo v\u0161eobecnosti z\u00e1viseli od d\u00e1vky. Ozn\u00e1menia o predbe\u017en\u00fdch v\u00fdsledkoch 3. f\u00e1zy poskytuj\u00fa d\u00f4le\u017eit\u00e9 \u00fadaje, ale podrobn\u00e9 recenzovan\u00e9 publik\u00e1cie zost\u00e1vaj\u00fa pevnej\u0161\u00edm z\u00e1kladom na hodnotenie met\u00f3d, \u00fa\u010dinkov v podskupin\u00e1ch a obmedzen\u00ed.<\/div>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-kicker\">Vybran\u00e1 literat\u00fara<\/div>\n<h2>V\u00fdskum a publik\u00e1cie<\/h2>\n<ol class=\"vl-refs\">\n<li><strong>Urva S a kol.<\/strong> LY3437943, nov\u00fd trojit\u00fd agonista receptorov pre GIP, GLP-1 a glukag\u00f3n: skor\u00e1 klinick\u00e1 farmakol\u00f3gia a d\u00f4kaz koncepcie. <em>Bunkov\u00fd metabolizmus<\/em> (2022). <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36354040\/\" target=\"_blank\" rel=\"noopener\">Z\u00e1znam v datab\u00e1ze PubMed<\/a>.<\/li>\n<li><strong>Rosenstock J et al.<\/strong> GLP3 u \u013eud\u00ed s diabetom 2. typu: randomizovan\u00e1 \u0161t\u00fadia f\u00e1zy 2. <em>The Lancet<\/em> (2023);402:529\u2013544. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37385280\/\" target=\"_blank\" rel=\"noopener\">Z\u00e1znam v datab\u00e1ze PubMed<\/a>.<\/li>\n<li><strong>Jastreboff AM a kol.<\/strong> Trojit\u00fd agonista horm\u00f3nov\u00fdch receptorov GLP3 pre obezitu \u2013 \u0161t\u00fadia f\u00e1zy 2. <em>New England Journal of Medicine<\/em> (2023);389:514\u2013526. <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\">Cel\u00e1 publik\u00e1cia<\/a>.<\/li>\n<li><strong>Sanyal AJ et al.<\/strong> Trojit\u00fd agonista hormon\u00e1lneho receptora GLP3 pre steat\u00f3zne ochorenie pe\u010dene spojen\u00e9 s metabolickou dysfunkciou: Pod\u0161t\u00fadia f\u00e1zy 2. <em>Nature Medicine<\/em> (2024). <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38858523\/\" target=\"_blank\" rel=\"noopener\">Z\u00e1znam v datab\u00e1ze PubMed<\/a>.<\/li>\n<li><strong>Klinick\u00fd program TRIUMPH.<\/strong> Aktu\u00e1lne \u0161t\u00fadie f\u00e1zy 3 a registrovan\u00e9 protokoly. <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05882045\" target=\"_blank\" rel=\"noopener\">ClinicalTrials.gov<\/a>.<\/li>\n<\/ol>\n<p class=\"vl-note\">Polo\u017eky f\u00e1zy 3 s\u00fa jasne identifikovan\u00e9 ako \u00fadaje o najvy\u0161\u0161\u00edch hodnot\u00e1ch hl\u00e1sen\u00e9 spolo\u010dnos\u0165ou alebo recenzovan\u00e9 publik\u00e1cie, tak\u017ee \u010ditatelia m\u00f4\u017eu vidie\u0165 zdroj a \u0161t\u00e1dium ka\u017ed\u00e9ho v\u00fdsledku.<\/p>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-coa\">\n<div>\n<div class=\"vl-kicker\">Transparentnos\u0165 \u0161pecifick\u00e1 pre dan\u00fa \u0161ar\u017eu<\/div>\n<h2>Nez\u00e1visl\u00e9 laborat\u00f3rne testovanie<\/h2>\n<p>Analytick\u00fd panel ni\u017e\u0161ie predstavuje testovan\u00fa 10 mg \u0161ar\u017eu RT10-26001. Ka\u017ed\u00e1 \u010fal\u0161ia sila a v\u00fdrobn\u00e1 \u0161ar\u017ea je prepojen\u00e1 s vlastn\u00fdm identifik\u00e1torom \u0161ar\u017ee a laborat\u00f3rnou spr\u00e1vou.<\/p>\n<p><a class=\"vl-btn\" href=\"\/sk\/lab-results\/\">Zobrazi\u0165 laborat\u00f3rne v\u00fdsledky d\u00e1vky<\/a><\/p>\n<\/div>\n<div class=\"vl-metrics\">\n<div class=\"vl-metric\"><span class=\"vl-label\">D\u00e1vka<\/span><strong>RT10-26001<\/strong><\/div>\n<div class=\"vl-metric\"><span class=\"vl-label\">Vyhl\u00e1sen\u00e9<\/span><strong>10 mg<\/strong><\/div>\n<div class=\"vl-metric\"><span class=\"vl-label\">Nameran\u00e9<\/span><strong>10,43 mg<\/strong><\/div>\n<div class=\"vl-metric\"><span class=\"vl-label\">\u010cistota<\/span><strong>99.7%<\/strong><\/div>\n<div class=\"vl-metric\"><span class=\"vl-label\">D\u00e1tum testu<\/span><strong>14. aug. 2026<\/strong><\/div>\n<div class=\"vl-metric\"><span class=\"vl-label\">Rozsah<\/span><strong>Jedna d\u00e1vka<\/strong><\/div>\n<\/div>\n<\/div>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-status\">\n<div class=\"vl-kicker\">Stav v\u00fdskumu \u00b7 D\u00f4le\u017eit\u00e9 inform\u00e1cie<\/div>\n<h3>Sk\u00faman\u00e1 molekula vo v\u00fdvoji f\u00e1zy 3<\/h3>\n<p>Len na laborat\u00f3rny a analytick\u00fd v\u00fdskum. Nie je ur\u010den\u00e9 na hum\u00e1nne ani veterin\u00e1rne pou\u017eitie.<\/p>\n<\/div>\n<\/section>\n<\/div>","protected":false},"excerpt":{"rendered":"<p><strong>Retatrutide (RETA), supplied as GLP3-R3TA, is a research peptide studied mainly in weight regulation, appetite and metabolism.<\/strong><\/p>\n<p>Jednoducho povedan\u00e9, v\u00fdskumn\u00edci sk\u00famaj\u00fa, ako tri prepojen\u00e9 sign\u00e1ly m\u00f4\u017eu ovplyvni\u0165 hlad, sp\u00f4sob spracovania \u017eiv\u00edn a mno\u017estvo energie, ktor\u00e9 telo vyu\u017e\u00edva.<\/p>\n<p><strong>Oblasti v\u00fdskumu:<\/strong> Regul\u00e1cia telesnej hmotnosti \u00b7 Chu\u0165 do jedla \u00b7 Metabolizmus gluk\u00f3zy a lipidov<\/p>","protected":false},"featured_media":560,"comment_status":"open","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[18,20],"product_tag":[],"class_list":["post-172","product","type-product","status-publish","has-post-thumbnail","product_cat-research-peptides","product_cat-weight-metabolism-research","desktop-align-center","tablet-align-center","mobile-align-left","first","instock","shipping-taxable","purchasable","product-type-variable"],"_links":{"self":[{"href":"https:\/\/www.veyronalabs.com\/sk\/wp-json\/wp\/v2\/product\/172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.veyronalabs.com\/sk\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/www.veyronalabs.com\/sk\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/www.veyronalabs.com\/sk\/wp-json\/wp\/v2\/comments?post=172"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veyronalabs.com\/sk\/wp-json\/wp\/v2\/media\/560"}],"wp:attachment":[{"href":"https:\/\/www.veyronalabs.com\/sk\/wp-json\/wp\/v2\/media?parent=172"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/www.veyronalabs.com\/sk\/wp-json\/wp\/v2\/product_brand?post=172"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/www.veyronalabs.com\/sk\/wp-json\/wp\/v2\/product_cat?post=172"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/www.veyronalabs.com\/sk\/wp-json\/wp\/v2\/product_tag?post=172"}],"curies":[{"name":"pracovn\u00fd list","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}